Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 4 1Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Leukemia 32Gastrointestinal Stromal Tumors 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 21Blast Crisis 9Philadelphia Chromosome 8Neoplasm Metastasis 8Melanoma 8Lung Neoplasms 8Brain Neoplasms 7Sarcoma 6Prostatic Neoplasms 6Neoplasms 6Recurrence 5Ovarian Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myeloid 4Dermatofibrosarcoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

Cyclophosphamide 53fludarabine phosphate 50Tacrolimus 41Busulfan 41Peripheral Blood Stem Cell Transplantation 37Mycophenolic Acid 36Whole-Body Irradiation 34Antilymphocyte Serum 34Cyclosporine 27Methotrexate 25fludarabine 24Melphalan 20Radiotherapy 19Filgrastim 16Methylprednisolone 14Cord Blood Stem Cell Transplantation 12Cytarabine 11thymoglobulin 10ruxolitinib 10Specimen Handling 10Biopsy 10Cyclosporins 9sargramostim 8Sirolimus 8Etoposide 8Alemtuzumab 8Thiotepa 7Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myeloproliferative Disorders × Imatinib Mesylate × Clear all
NCT00245128 2012-01-13

Imatinib Mesylate in Treating Patients With Myelofibrosis

OHSU Knight Cancer Institute

Phase 2 Terminated
10 enrolled 6 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡